Related Articles
Tiam1, overexpressed in most malignancies, is a novel tumor biomarker
MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells pulsed with recombinant adeno-associated virus carrying α-fetoprotein gene or cancer cell lysate
MHC class I down-regulation: tumour escape from immune surveillance? (Review)
Tumour MHC class I downregulation and immunotherapy (Review)